
    
      Patients entering the study will signed an informed consent and will undergo bone marrow
      aspiration and peripheral blood examination. On both these two tissues the MRD analysis
      reaching for myeloma cells.

      During the treatment period, all patients will attend study center visits every 4 weeks,
      until development of confirmed Progressive Disease (PD). During this visits the patients will
      undergo physical evaluation and routine blood control will be performed to monitor response
      to therapy and side effects.

      When a patient develops a PD requiring the beginning of a new treatment, the patient
      interrupts the MRD monitoring but will be followed for survival every 2 months via telephone
      or office visit.
    
  